Form 8-K

8-K — BioXcel Therapeutics, Inc.

Accession: 0001104659-26-061773

Filed: 2026-05-15

Period: 2026-05-15

CIK: 0001720893

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2614679d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2614679d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2614679d1_8k.htm · Sequence: 1

false

0001720893

2026-05-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 15, 2026

BioXcel

Therapeutics, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-38410

82-1386754

(State

or other jurisdiction of

incorporation)

(Commission

File Number)

(I.R.S.

Employer

Identification No.)

555

Long Wharf Drive

New

Haven, CT 06511

(Address of principal executive offices, including

Zip Code)

(475)

238-6837

(Registrant’s telephone number, including

area code)

N/A

(Former name or former address, if changed

since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

¨ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered

pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

Stock, par value $0.001

BTAI

The Nasdaq

Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On May 15, 2026, BioXcel Therapeutics, Inc. (the

“Company”) issued a press release announcing its financial results for the three months ended March 31, 2026 and provided

a business update. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated

herein by reference.

The information disclosed under this Item 2.02,

including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant

to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)   Exhibits.

Ex. No.

Description

99.1

Press release, dated May 15, 2026.

104

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Date: May 15, 2026

BIOXCEL THERAPEUTICS, INC.

/s/ Richard Steinhart

By: Richard Steinhart

Title:

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2614679d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

BioXcel Therapeutics

Provides Business Update and

Reports

First Quarter 2026 Financial Results

FDA accepted sNDA for IGALMI® use in at-home

(outpatient) setting; set Nov. 14, 2026, as PDUFA date

Advancing BXCL501 as a potential acute treatment

for agitation associated with Alzheimer’s dementia

Evaluating strategic options with an advisor

to maximize shareholder value and advance the commercial and development plans for IGALMI

NEW HAVEN, Conn., May 15, 2026 — BioXcel Therapeutics, Inc.

(Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in

neuroscience, today provided a business update and reported financial results for the first quarter of 2026. In the quarter ended on

March 31, the FDA accepted the Company’s supplemental New Drug Application (sNDA) for IGALMI® for at-home use in the acute

treatment of agitation associated with bipolar disorders or schizophrenia and assigned a PDUFA target action date of November 14, 2026.

“The first quarter was marked by tremendous progress, achieving

a major regulatory milestone and developing the IGALMI commercial launch plan for the at-home setting,” said Vimal Mehta, Ph.D.,

Chief Executive Officer of BioXcel Therapeutics. “We are very pleased with the recent approval of another product in Alzheimer’s

agitation, in an area adjacent to our focus on the acute treatment of agitation in Alzheimer’s dementia with BXCL501. Our first-in-class

mechanism has the potential to make a transformative impact on the lives of a large patient population in this disease area. We are actively

pursuing strategic options to maximize shareholder value for the IGALMI franchise.”

Strategic Options

· Exploring

Value-Maximizing Options: The Company engaged MTS Health Partners as an advisor for evaluation

of strategic options to maximize shareholder value and advance the commercial and development

plans for IGALMI, which may include, but are not limited to, a sale of the Company, a merger

or other business combination, a collaboration, joint venture, royalty or license agreement

of all or a portion of our assets, a recapitalization or other financing transaction, or

continued execution of our standalone operating plan. We have not made a decision to pursue

any specific transaction or strategic option, no set timetable has been established for the

completion of this process, and there can be no assurance that the process will result in

any transaction or other particular outcome.

BXCL501

Late-Stage Clinical Programs

SERENITY Program

· FDA

Acceptance of IGALMI At-Home sNDA: The FDA recently accepted the Company’s sNDA

seeking to expand the IGALMI label for the at-home treatment of acute agitation in bipolar

disorder and schizophrenia. The FDA has assigned a PDUFA target action date of November 14,

2026, which, if approved, would represent the first FDA-approved treatment option for acute

agitation associated with bipolar disorders or schizophrenia in the at-home setting.

· Commercial

Launch Readiness: The Company has been preparing for the commercial launch and has developed

a comprehensive launch plan, informed by a third-party market assessment highlighting a large

total addressable market for IGALMI in the at-home setting. The Company recently hosted a

virtual event, held by a covering analyst, to present the launch plans and discuss

the market opportunity with investors.

TRANQUILITY Program

· TRANQUILITY

In-Care Phase 3 Trial: The TRANQUILITY In-Care trial is designed as a double-blind, placebo-controlled

study to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for the acute treatment

of agitation associated with Alzheimer’s dementia. The Company remains focused on BXCL501’s

potential in this disease, supported by a favorable regulatory environment following a recent

FDA approval in an adjacent indication, which is further reinforcing the need in this therapeutic

area.

First Quarter 2026 Financial Results

Net revenue from IGALMI® was $206,000 for the first quarter

of 2026, compared to $168,000 for the same period in 2025. The Company is focused on preparing for IGALMI’s launch in the at-home

setting and maintaining IGALMI’s brand awareness with minimal commercial resources.

Cost of Goods Sold for the first quarter of 2026 was $283,000,

compared to $14,000 for the same period in 2025. The increase in Cost of Goods Sold for the first quarter is primarily the result of

higher charges for reserves for excess or obsolete inventory compared to the same respective period in 2025.

Research and Development (R&D) expenses were $3.0 million

for the first quarter of 2026, compared to $4.6 million for the same period in 2025. The decreased expenses for the first quarter of

2026 were primarily due to the completion of the SERENITY At-Home pivotal Phase 3 safety trial in 2025.

Selling, General and Administrative (SG&A) expenses were

$7.2 million for the first quarter of 2026, compared to $5.7 million for the same period in 2025. The increased costs for the first quarter

of 2026 were primarily attributable to an increase in professional fees.

Net Loss: BioXcel Therapeutics reported an operating loss of

$10.2 million and a net loss of $12.7 million for the first quarter of 2026, compared to an operating loss of $10.1 million and net loss

of $7.3 million for the same period in 2025.

Cash and cash equivalents and restricted cash totaled $17.2

million as of March 31, 2026.

The

Company remains in compliance with the covenants in its Credit Agreement.

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company

built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience. Its wholly owned subsidiary,

OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach

leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning

algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.

About BXCL501

Outside of its approved indication by the U.S. Food and Drug Administration

as IGALMI® (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film formulation

of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BXCL501 is under investigation by BioXcel Therapeutics for the acute

treatment of agitation associated with Alzheimer’s dementia and for the acute treatment of agitation associated with bipolar I

or II disorder or schizophrenia in the at-home setting. The safety and efficacy of BXCL501 for these investigational uses have not been

established. BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with

dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia.

About IGALMI® (dexmedetomidine) sublingual

film

IGALMI® (dexmedetomidine) sublingual film is a

prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower

lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety

and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective

in children.

IMPORTANT SAFETY INFORMATION

IGALMI can cause serious side effects, including:

· Decreased

blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low

blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider

who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling

or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider

if they feel dizzy, lightheaded, or faint.

· Heart

rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an

irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI

with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed

to tell their healthcare provider immediately if they feel faint or have heart palpitations.

· Sleepiness/drowsiness.

Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours

after taking IGALMI.

· Withdrawal

reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical

dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer

than 24 hours.

The most common side effects of IGALMI in clinical studies

were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure,

and low blood pressure upon standing.

These are not all the possible side effects of IGALMI. Patients

should speak with their healthcare provider for medical advice about side effects.

Patients should tell their healthcare provider about their medical

history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate,

diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are

pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take

anesthetics, sedatives, hypnotics, and opioids.

Everyone is encouraged to report negative side effects of prescription

drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088

or medinfo@bioxceltherapeutics.com.

Please see full prescribing information at Igalmi.com.

About the SERENITY At-Home Phase 3 Trial

The SERENITY At-Home Phase 3 trial is a double-blind, placebo-controlled

study designed to evaluate the safety of a 120-mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders

or schizophrenia in the at-home setting. The trial is designed to evaluate 200 patients with a history of agitation episodes residing

at home either alone or with caregivers/informants. Patients are self-administering 120-mcg of BXCL501 or placebo when agitation episodes

occur over the 12-week trial period, with safety data (adverse events) collected during the trial. In addition, patients or caregivers/informants

will complete a modified global impression of severity (mCGIs) and a clinical global impression of change (mCGI-C) two hours after dosing

as an exploratory endpoint to evaluate use in the outpatient setting.

About the TRANQUILITY In-Care Phase 3 Trial

The TRANQUILITY In-Care trial is designed as a double-blind, placebo-controlled

study to evaluate the efficacy and safety of a 60-mcg dose of BXCL501 over a 12-week period for agitation associated with Alzheimer’s

dementia in the care setting. The trial is expected to enroll approximately 150 patients 55 years and older who have mild, moderate,

or severe dementia with mini-mental state examination scores of 0 to 25 and who reside in skilled nursing facilities, memory care units,

or assisted living facilities. Patients will self-administer 60-mcg of BXCL501 or placebo when episodic agitation episodes occur over

the trial period. The primary endpoint is expected to be a change from baseline in the Positive and Negative Syndrome Scale-Excitatory

Component (PEC) total score at two hours post-first dose. Additional PEC and Clinical Global Impressions – Improvement Scale measurements

will also be obtained during the trial.

Forward-Looking Statements

This press release includes “forward-looking statements”

within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by

the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section

21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical

fact should be considered forward-looking statements, including, without limitation, statements related to: approval by the FDA of the

sNDA and expanded label for IGALMI, IGALMI’s ability to make a transformative impact on the lives of a large patient population,

ability to advance a strategic option to maximize shareholder value and advance the commercial and development plans for IGALMI. When

used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,”

“designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,”

“may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,”

“should,” “target,” “will,” “would” and similar expressions are intended to identify

forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or

information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events

or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s

current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but

they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could

differ materially from those described or implied by such forward-looking statements as a result of various important factors, including,

without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding

and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant

obligations and potential payment obligations related to such indebtedness and other contractual obligations; the Company has identified

conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery

and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI®,

BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; the number of episodes of agitation and the size of the Company’s

total addressable market may be overestimated, and approval that the Company may obtain may be based on a narrower definition of the

patient population; its lack of experience in marketing and selling drug products; the risk that IGALMI® or the Company’s

product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing

regulatory requirements and obligations for IGALMI®; the failure of preliminary data from its clinical studies to predict

final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to

receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects

caused by the Company’s product candidates; its novel approach to the discovery and development of product candidates based on

EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement lawsuits; its reliance on

third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if

any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with

federal, state or foreign health care “fraud and abuse” laws; and its ability to commercialize its product candidates, as

well as the important factors discussed under the caption “Risk Factors” in its Annual Report on Form 10-K for the fiscal

year ended December 31, 2025, as such factors may be updated from time to time in its other filings with the SEC, which are accessible

on the SEC’s website at and the Investors section of the Company’s website at. These and other important factors could cause

actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking

statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking

statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause

our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date

subsequent to the date of this press release.

Contact Information:

Corporate/Investors

Russo Partners

Nic Johnson

nic.johnson@russopartnersllc.com

1.303.482.6405

Media

Russo Partners

David Schull

david.schull@russopartnersllc.com

1.858.717.2310

Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc.

Statements

of Operations

(Unaudited, in thousands, except per share amounts)

Three months ended March 31,

2026

2025

Revenues

Product revenues

$ 206

$ 168

Operating expenses

Cost of goods sold

283

Research and development

2,955

4,554

Selling, general and administrative

7,191

5,699

Restructuring costs

Total operating expenses

10,429

10,267

Loss from operations

(10,223 )

(10,099 )

Other (income) expense

Interest expense, net

4,198

3,993

Interest income

(211 )

(279 )

Other (income) expense, net

(1,519 )

(6,559 )

Net loss and comprehensive loss

$ (12,691 )

$ (7,254 )

Net loss per share - basic and diluted

$ (0.54 )

$ (1.50 )

Weighted average shares outstanding - basic and diluted

23,571

4,834

Condensed Balance Sheets

(Unaudited, in thousands)

March 31,

December 31,

2026

2025

Cash and cash equivalents and restricted cash

$ 17,180

$ 28,757

Total assets

$ 34,025

$ 44,916

Total liabilities

$ 139,568

$ 140,379

Total stockholders' equity (deficit)

$ (105,543 )

$ (95,463 )

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 15, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 15, 2026

Entity File Number

001-38410

Entity Registrant Name

BioXcel

Therapeutics, Inc.

Entity Central Index Key

0001720893

Entity Tax Identification Number

82-1386754

Entity Incorporation, State or Country Code

Entity Address, Address Line One

555

Long Wharf Drive

Entity Address, City or Town

New

Haven

Entity Address, State or Province

Entity Address, Postal Zip Code

06511

City Area Code

475

Local Phone Number

238-6837

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001

Trading Symbol

BTAI

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration